TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Researchers mapped immune-aging patterns and found that a blood-protein model indicating more granzyme B-producing than granzyme K-producing T cells was associated with higher rates of later chronic disease and death. The findings are observational and do not establish a diagnosis or prove that the cell pattern causes illness; a practical blood test is still in development.
Researchers have mapped a range of human immune-aging patterns and linked a blood-protein signature associated with one immune-cell balance to higher rates of chronic illness and death over the following decade. The study, published Oct. 9 in Immunity, suggests the pattern could help identify differences in health trajectories before a clinical diagnosis, but it is not a diagnostic test and does not show that the immune pattern causes disease.
The research team, led by scientists at Washington University School of Medicine in St. Louis, Nationwide Children’s Hospital and King’s College London, analyzed about 12.4 million immune cells from 2,609 mostly healthy adults aged 20 to over 90. The participants came from eight cohorts in North America, the United Kingdom, Asia and Australia. The researchers found that immune profiles varied among older adults, including in the balance of cells associated with different inflammatory and immune-response patterns.
The map focused on two kinds of effector memory CD8 T cells, distinguished by the granzyme proteins they produce. Granzyme B-producing cells can directly destroy diseased cells, while granzyme K-producing cells may help signal for other immune responses, the report said. The researchers placed people along a spectrum based on the relative abundance of these cell types.
To examine later health outcomes, the team built a computer model using a smaller dataset that included CD8 T-cell counts and blood proteins. It applied the model to baseline protein samples from 50,000 UK Biobank participants, then compared the estimates with up to 15 years of medical records. Participants whose modeled profiles leaned toward granzyme B cells had higher subsequent risks of death and of conditions including type 2 diabetes, hypertension, liver disease and renal failure than those leaning toward granzyme K cells. The study report does not provide effect sizes in the supplied material.
A Possible Signal Before Diagnosis
The findings may offer a way to study why people of similar ages experience different health outcomes. A blood-based indicator of immune aging could, if validated and made practical, help researchers and clinicians identify people who may need closer monitoring before symptoms or a formal diagnosis emerge. That possibility matters because the study connected baseline immune profiles with health records collected over many years.
For now, the results are best understood as an association and research signal, not a personal forecast. The study does not show that changing the ratio of these cells would prevent chronic disease, nor does it establish that an individual with a granzyme B-leaning profile will become ill. Researchers say the current mapping approach relies on specialized, complex technology; the proposed accessible test has not yet been shown to work in routine care.
As an affiliate, we earn on qualifying purchases.
How Researchers Built the Map
In the study, younger participants’ blood was generally richer in naive immune cells, which have not yet encountered specific pathogens and can respond to new infections or vaccines. Older participants showed more varied profiles, with some having greater levels of cells associated with inflammation. The authors describe immune aging as a spectrum rather than a change that happens at the same rate for everyone.
The long-term analysis used the UK Biobank, which follows about 500,000 people recruited at ages 40 to 69 and records health events. Because its data did not include direct counts of CD8 T cells for the relevant analysis, the researchers trained a model on a separate dataset with both cell counts and blood-protein measurements. They then used that model to estimate participants’ positions on the cell spectrum from stored baseline protein samples. The resulting estimates, rather than direct cell counts for those 50,000 people, were compared with their subsequent medical histories.
“We have found that there are clues in the blood that can tell us whether someone is on a healthy or unhealthy aging trajectory.”
— Maxim N. Artyomov, study co-corresponding author and professor of pathology and immunology at Washington University School of Medicine
As an affiliate, we earn on qualifying purchases.
Limits of the Risk Estimate
The findings show that a modeled immune-cell pattern was associated with later health outcomes; they do not establish cause and effect. The supplied report does not give the size of the increased risks, detail how the association varied among participant groups, or establish how accurately the model predicts outcomes for an individual. It also does not show whether the results apply equally across populations beyond those studied.
The UK Biobank analysis inferred cell-spectrum positions from blood proteins because direct CD8 T-cell counts were unavailable for that large group. The authors’ proposed test remains under development, and the report does not provide a timeline, validation results, cost, or a threshold for clinical use. It is not yet clear whether acting on the signal would reduce disease risk.
As an affiliate, we earn on qualifying purchases.
From Research Model to Blood Test
Artyomov and his lab are adapting the research toward a blood test that could be processed with standard equipment. The next steps will need to establish whether such a test can reliably measure the relevant immune pattern, predict outcomes in independent populations and provide information that improves clinical decisions. The report gives no launch date or evidence that the test is currently available to patients.
Until that work is completed, the study’s main contribution is a map and a long-term association that can guide further research. Any future use in preventive care will depend on validation of the test and evidence that monitoring or follow-up based on its results benefits patients.
blood protein testing for chronic disease risk
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the immune-aging study find?
Researchers found that a modeled profile leaning toward granzyme B-producing CD8 T cells was associated with higher rates of death and several chronic conditions over the following decade, compared with a profile leaning toward granzyme K-producing cells.
Does a granzyme B-leaning profile mean someone has a disease?
No. The researchers describe the pattern as a possible sign of immune stress, not a formal diagnosis. The study does not establish that an individual with this profile will develop a particular condition.
Is the proposed blood test available now?
No availability was reported. The research team said it is adapting the work into a test that could use standard equipment, but the test remains in development.
How did researchers estimate immune patterns in UK Biobank participants?
They built a computer model using a smaller dataset with both CD8 T-cell counts and blood-protein measurements, then applied it to baseline protein samples from 50,000 UK Biobank participants. The estimated profiles were compared with up to 15 years of health records.
Does the study show that the immune-cell balance causes chronic disease?
No. It reports an association between modeled immune profiles and later outcomes. It does not establish causation or show that changing the cell balance would prevent disease.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
